1. Judging journals' impact.

    The lancet. Diabetes & endocrinology 3(8):590 (2015) PMID 26134686

  2. Diabetes, obesity, and the metabolic syndrome: a call for papers for EASD and the World Diabetes Congress.

    The lancet. Diabetes & endocrinology 3(8):591 (2015) PMID 26144066

  3. Global Surgery 2030: Evidence and solutions for achieving health, welfare, and economic development.

    Surgery 158(1):3 (2015) PMID 25987187

  4. The Lancet Diabetes & Endocrinology needs a more rigorous conflict of interest policy – Editors' reply

    The Lancet Diabetes & Endocrinology 3(3):168 (2015)

  5. The Lancet Diabetes & Endocrinology needs a more rigorous conflict of interest policy - Editors' reply.

    The lancet. Diabetes & endocrinology 3(3):168 (2015) PMID 25702246

  6. The Lancet Diabetes & Endocrinology needs a more rigorous conflict of interest policy - Editors' reply.

    The lancet. Diabetes & endocrinology 3(3):168 (2015) PMID 25702246

  7. A time for reflection and thanks.

    The lancet. Diabetes & endocrinology 2(11):853 (2014) PMID 25439458

  8. A time for reflection and thanks.

    The lancet. Diabetes & endocrinology 2(11):853 (2014) PMID 25439458

  9. A time for reflection and thanks.

    The lancet. Diabetes & endocrinology 2(11):853 (2014) PMID 25439458

  10. Getting to grips with the weighty problem of obesity: a call for papers

    The lancet global health 2(3):e138 (2014) PMID 25102842

  11. Getting to grips with the weighty problem of obesity: a call for papers

    The lancet global health 2(3):e138 (2014) PMID 25102842

  12. Diabetes--a call for research papers.

    The lancet. Diabetes & endocrinology 1(4):272 (2013) PMID 24622410

  13. Diabetes—a call for research papers

    The Lancet 382(9904):1543 (2013)

  14. Diabetes—a call for research papers

    The Lancet 382(9904):1543 (2013)

  15. Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma.

    Cancer Research 73(2):885 (2013) PMID 23204224 PMCID PMC3548986

    Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy that resists current treatments. To test epigenetic therapy against this cancer, we used the DNA demethylating drug 5-aza-2'-deoxycytidine (DAC) in an aggressive mouse model of stromal rich PDAC (KPC-Brca1 mice). In untreated tumors,...
  16. Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma.

    Cancer Research 73(2):885 (2013) PMID 23204224 PMCID PMC3548986

    Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy that resists current treatments. To test epigenetic therapy against this cancer, we used the DNA demethylating drug 5-aza-2'-deoxycytidine (DAC) in an aggressive mouse model of stromal rich PDAC (KPC-Brca1 mice). In untreated tumors,...
  17. Elmi Muller: bending rules, changing guidelines, making history.

    The Lancet 379(9828):1781 (2012) PMID 22579311

  18. Elmi Muller: bending rules, changing guidelines, making history

    The Lancet 379(9828):1781 (2012)

  19. Elmi Muller: bending rules, changing guidelines, making history.

    The Lancet 379(9828):1781 (2012) PMID 22579311

  20. Stefan Willich: conductor and cardiologist

    The Lancet 379(9824):1383 (2012)